Cerebral 18F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune

Yifei Ma1, Jiling Zeng2,3, Fadian Ding1

  • 1Department of Hepatobiliary and Pancreatic Surgery, Institute of Abdominal Surgery, Fujian Provincial Key Laboratory of Precision Medicine for Cancer, and Department of Hepatobiliary and Pancreatic Surgery, National Regional Medical Center Binhai Campus, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Insights

Immune checkpoint inhibitors (ICI) can cause central nervous system toxicity (CNST). 18F-FDG PET/CT scans detect brain hypermetabolism before and during CNST onset, aiding early diagnosis in cancer patients.

Area of Science:

  • Neuro-oncology
  • Nuclear Medicine
  • Radiology

Background:

  • Immune checkpoint inhibitors (ICI) are crucial in cancer therapy but can cause immune-related central nervous system toxicity (CNST).
  • Early identification of CNST is challenging, necessitating reliable biomarkers.
  • 18F-FDG PET/CT imaging offers a potential tool for assessing brain metabolic changes.

Purpose of the Study:

  • To identify potential biomarkers for ICI-related CNST using 18F-FDG PET/CT.
  • To differentiate CNST from central nervous system infections (CNSIs) and from no neurological events.
  • To evaluate the predictive value of early metabolic changes for later CNST onset.

Main Methods:

  • A multicenter observational study analyzed 18F-FDG PET/CT scans in cancer patients treated with ICI.
  • Regional SUVmean changes in brain lobes were compared between CNST+ patients, CNST- patients, and CNSIs patients using propensity score matching.
  • A validation cohort assessed early metabolic changes (5-6 weeks post-therapy) for predicting CNST incidence.

Main Results:

  • 18F-FDG PET/CT identified higher regional SUVmean changes in CNST+ versus CNST- patients (AUC 0.83) and CNSI patients (AUC 0.80).
  • Metabolic changes were detectable before CNST onset (AUC 0.74 for CNST+ vs. CNST-).
  • In the validation cohort, early metabolic changes predicted later CNST incidence (AUC 0.86).

Conclusions:

  • Brain regional hypermetabolism is detectable before and during clinical onset of ICI-related CNST.
  • 18F-FDG PET/CT findings suggest CNST is a distinct entity from brain infections.
  • Regional metabolic differences show potential for developing early diagnostic tools for CNST.